NCT04647890View on ClinicalTrials.gov

Effects of FT011 in Systemic Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

July 19, 2021

Primary Completion Date

October 12, 2022

Study Completion Date

November 16, 2022

Conditions
Scleroderma, SystemicScleroderma, DiffuseSclerosis, Systemic
Interventions
DRUG

FT011

Two x 100mg capsules once daily for 12 weeks

DRUG

FT011

Two x 200mg capsules once daily for 12 weeks

DRUG

Placebo

Two placebo capsules once daily for 12 weeks

Trial Locations (10)

3065

St Vincent's Hospital Melbourne, Fitzroy

5000

Royal Adelaide Hospital, Adelaide

Unknown

Certa SSc trial site, Nijmegen

Certa SSc trial site, Bydgoszcz

Certa SSc trial site, Krakow

Certa SSc trial site, Malbork

Certa SSc trial site, Warsaw

Certa SSc trial site, Barcelona

Certa SSc trial site, Kyiv

Certa SSc trial site, Poltava

Sponsors

Lead Sponsor

Certa Therapeutics
All Listed Sponsors
lead

Certa Therapeutics

INDUSTRY